NCT01560793View on ClinicalTrials.gov

Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years

PHASE1CompletedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

November 30, 2013

Conditions
Influenza
Interventions
BIOLOGICAL

VAX161 [STF2.HA5 H5N1]

dose escalating, 2 intramuscular doses given 21 days apart

Trial Locations (2)

33143

Miami Research Associates, Miami

66219

Johnson County Clin-Trials, Lenexa

All Listed Sponsors
lead

VaxInnate Corporation

INDUSTRY

NCT01560793 - Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years | Biotech Hunter | Biotech Hunter